|
MAL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.05859999999636E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.56535999999985E-05 |
| Normal-vs-Stage2 |
3.87569998316906E-09 |
| Normal-vs-Stage3 |
2.756700E-04 |
| Normal-vs-Stage4 |
3.92959999999665E-05 |
| Stage1-vs-Stage2 |
1.097860E-02 |
| Stage1-vs-Stage3 |
5.960600E-01 |
| Stage1-vs-Stage4 |
7.335200E-01 |
| Stage2-vs-Stage3 |
6.203400E-03 |
| Stage2-vs-Stage4 |
3.340100E-02 |
| Stage3-vs-Stage4 |
5.102800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.77299999999781E-05 |
| Normal-vs-AfricanAmerican |
1.417830E-03 |
| Normal-vs-Asian |
2.48570000005444E-06 |
| Caucasian-vs-AfricanAmerican |
6.470400E-01 |
| Caucasian-vs-Asian |
1.269150E-01 |
| AfricanAmerican-vs-Asian |
5.112200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.98520000002944E-06 |
| Normal-vs-Female |
8.77900000029186E-07 |
| Male-vs-Female |
5.687600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.831700E-04 |
| Normal-vs-Age(41-60Yrs) |
6.03910000007701E-07 |
| Normal-vs-Age(61-80Yrs) |
2.73980005349728E-09 |
| Normal-vs-Age(81-100Yrs) |
9.438200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.909030E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.740900E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.758000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.140210E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.251800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.574800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.906430E-01 |
| Classical-VS-Follicular |
4.26710000667185E-09 |
| Classical-VS-Other |
9.133200E-01 |
| Classical-VS-Normal |
1.218180E-04 |
| Tall-VS-Follicular |
2.05880000003766E-06 |
| Tall-VS-Other |
4.823600E-01 |
| Tall-VS-Normal |
1.291200E-01 |
| Follicular-VS-Other |
6.381600E-02 |
| Follicular-VS-Normal |
1.80988557474393E-12 |
| Other-VS-Normal |
9.245500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.99700050834895E-10 |
| Normal-vs-N1 |
2.599600E-03 |
| N0-vs-N1 |
5.040000E-02 |
|
|
